

Vidya Perera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6728536/publications.pdf>

Version: 2024-02-01

25
papers

881
citations

623574

14
h-index

642610

23
g-index

25
all docs

25
docs citations

25
times ranked

1414
citing authors

#	ARTICLE	IF	CITATIONS
1	First-in-human study of milvexian, an oral, direct, small molecule factor Xla inhibitor. Clinical and Translational Science, 2022, 15, 330-342.	1.5	45
2	Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants. Clinical Pharmacokinetics, 2022, 61, 857-867.	1.6	16
3	Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants. Scientific Reports, 2022, 12, 5165.	1.6	6
4	Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor Xla Inhibitor. Cardiology and Therapy, 2022, 11, 407-419.	1.1	10
5	Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. Clinical Pharmacokinetics, 2020, 59, 1013-1026.	1.6	3
6	Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients. American Journal of Transplantation, 2019, 19, 1218-1223.	2.6	16
7	First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor Xla inhibitor in non-Japanese and Japanese healthy subjects. British Journal of Clinical Pharmacology, 2018, 84, 876-887.	1.1	40
8	Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. British Journal of Clinical Pharmacology, 2018, 84, 462-476.	1.1	53
9	Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition. Drug Metabolism and Disposition, 2018, 46, 1075-1082.	1.7	44
10	Serious adverse drug reactions to zolpidem: does impaired metabolic clearance and concurrent SSRI/SNRI use increase risk?. Journal of Pharmacy Practice and Research, 2016, 46, 139-142.	0.5	3
11	Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. International Journal of Antimicrobial Agents, 2015, 45, 319-323.	1.1	14
12	Prediction of plasma caffeine concentrations in young adolescents following ingestion of caffeinated energy drinks: a Monte Carlo simulation. European Journal of Pediatrics, 2015, 174, 1671-1678.	1.3	7
13	Pharmacometrics: an underused resource in Australian clinical research. Medical Journal of Australia, 2014, 200, 82-83.	0.8	4
14	Terbinafine in Combination with Other Antifungal Agents for Treatment of Resistant or Refractory Mycoses: Investigating Optimal Dosing Regimens Using a Physiologically Based Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy, 2014, 58, 48-54.	1.4	34
15	Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. British Journal of Clinical Pharmacology, 2014, 78, 800-814.	1.1	15
16	High-Dose Olanzapine for Bipolar Depression. primary care companion for CNS disorders, The, 2014, 16, .	0.2	0
17	Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1115-1137.	1.5	34
18	A Pharmacometric Approach to Investigate the Impact of Methylxanthine Abstinence and Caffeine Consumption on CYP1A2 Activity. Drug Metabolism and Disposition, 2013, 41, 1957-1966.	1.7	8

#	ARTICLE	IF	CITATIONS
19	Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 65, 264-270.	1.2	13
20	Measurement of CYP1A2 Activity: A Focus on Caffeine as a Probe. <i>Current Drug Metabolism</i> , 2012, 13, 667-678.	0.7	66
21	Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 1161-1168.	1.2	58
22	Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. <i>Biomedical Chromatography</i> , 2010, 24, 1136-1144.	0.8	40
23	Frailty Should be Assessed Using Validated Scales. <i>Drugs and Aging</i> , 2010, 27, 687.	1.3	0
24	The assessment of frailty in older people in acute care. <i>Australasian Journal on Ageing</i> , 2009, 28, 182-188.	0.4	181
25	The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. <i>Age and Ageing</i> , 2008, 38, 156-162.	0.7	171